APA (7th ed.) Citation

Tourdot, B. E., Stoveken, H., Trumbo, D., Yeung, J., Kanthi, Y., Edelstein, L. C., . . . Holinstat, M. (2018). Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics. Arteriosclerosis, thrombosis, and vascular biology, 38(7), 1632-1643. https://doi.org/10.1161/ATVBAHA.118.311112

Chicago Style (17th ed.) Citation

Tourdot, Benjamin E., Hannah Stoveken, Derek Trumbo, Jennifer Yeung, Yogendra Kanthi, Leonard C. Edelstein, Paul F. Bray, Gregory G. Tall, and Michael Holinstat. "Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics." Arteriosclerosis, Thrombosis, and Vascular Biology 38, no. 7 (2018): 1632-1643. https://doi.org/10.1161/ATVBAHA.118.311112.

MLA (9th ed.) Citation

Tourdot, Benjamin E., et al. "Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 38, no. 7, 2018, pp. 1632-1643, https://doi.org/10.1161/ATVBAHA.118.311112.